Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.

View in: PubMed

subject areas

Adenosine Monophosphate
Administration, Oral
Aged
Cause of Death
Coronary Angiography
Coronary Artery Disease
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Global Health
Humans
Incidence
Infusions, Intravenous
Male
Middle Aged
Myocardial Infarction
Percutaneous Coronary Intervention
Postoperative Complications
Purinergic P2Y Receptor Antagonists
Survival Rate
Ticlopidine
Time Factors

authors with profiles

Robert Harrington